Abdelkader Samer, Voladri Divya R, Kennedy Joshua L
Arkansas Children's Research Institute, Little Rock, Arkansas; Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Ann Allergy Asthma Immunol. 2025 Sep;135(3):249-260. doi: 10.1016/j.anai.2025.06.012.
Asthma affects approximately 25 million people in the United States, with respiratory viruses playing a significant role in both the onset and exacerbations of the condition. Although rhinovirus and respiratory syncytial virus (RSV) are the most well-known triggers, other iratory viruses playing a significant role in both the on, human parainfluenza virus, human bocavirus, enterovirus D68, influenza, and SARS-CoV-2 are increasingly recognized for their significant impact on asthma. These viruses contribute to both the development of asthma and exacerbations by inducing airway inflammation, disrupting epithelial barriers, and skewing immune responses-particularly toward type 2 inflammation. Human metapneumovirus and human parainfluenza virus, members of the Paramyxoviridae family such as RSV, have been linked to early life wheezing and long-term airway changes. Although often co-detected with other viruses, human bocavirus has been associated with recurrent wheezing and asthma risk. Enterovirus D68, notably during the 2014 outbreak, caused severe exacerbations in children with asthma. Influenza and SARS-CoV-2 can cause significant morbidity in those with asthma, even if they are not the primary drivers of exacerbations or onset. As RSV vaccines become more widespread, shifts in viral ecology may lead to increased prevalence of these lesser known viruses due to viral interference and immunity gaps. Understanding their epidemiology and mechanisms is crucial for addressing the evolving asthma burden. Comprehensive surveillance, improved diagnostics, and mechanistic research are essential for developing effective preventive strategies. Broadening the focus beyond rhinovirus and RSV will be critical to fully understand and mitigate the impact of asthma on childrenng be critical to fth.
在美国,哮喘影响着约2500万人,呼吸道病毒在该疾病的发病和加重过程中起着重要作用。尽管鼻病毒和呼吸道合胞病毒(RSV)是最广为人知的触发因素,但其他呼吸道病毒,如人副流感病毒、人博卡病毒、肠道病毒D68、流感病毒和严重急性呼吸综合征冠状病毒2(SARS-CoV-2),因其对哮喘的重大影响而越来越受到认可。这些病毒通过诱导气道炎症、破坏上皮屏障和扭曲免疫反应(特别是向2型炎症方向),导致哮喘的发展和加重。人偏肺病毒和人副流感病毒是副粘病毒科的成员,与RSV一样,与早期生活中的喘息和长期气道变化有关。尽管人博卡病毒常与其他病毒共同检测到,但它与反复喘息和哮喘风险有关。肠道病毒D68,特别是在2014年疫情期间,导致哮喘儿童病情严重加重。流感病毒和SARS-CoV-2可使哮喘患者出现严重发病,即使它们不是病情加重或发病的主要驱动因素。随着RSV疫苗的更广泛使用,由于病毒干扰和免疫差距,病毒生态的变化可能导致这些鲜为人知的病毒患病率增加。了解它们的流行病学和发病机制对于应对不断变化的哮喘负担至关重要。全面监测、改进诊断方法和进行发病机制研究对于制定有效的预防策略至关重要。将关注点从鼻病毒和RSV扩大到其他病毒对于全面了解和减轻哮喘对儿童的影响至关重要。